Xunming Biotech completed a $35 million Series A+ financing round.

36Kr learned that "Xunming Biotech" recently completed a $35 million Series A+ financing round. This round of financing was led by HSG, with Matrix Partners and Boyuan Capital participating as follow-on investors. Existing shareholders such as Wuyuan Capital, Qiming Venture Partners, and New Leaf Capital continued to increase their investments. Xunming Biotech stated that the funds raised in this round will be used to promote the construction of its self-developed innovative functional antibody design platform AuraIDE™, strengthen the construction of the base model and agent capabilities, improve the facilities of the high-throughput and high-content experimental platform, and further connect the key links of the agent from project initiation, molecular design to transformation and implementation.